

TM CRUX European Fund

GBP factsheet August 2022

CRUX
ASSET MANAGEMENT

Fund Facts as at 31/08/22

Fund Objective

The Fund aims to achieve long-term capital growth by investing primarily in equities of European companies.

Launch Date

2 November 2015

Structure

OEIC

Fund Size

£55.3m

Performance comparator

IA Europe ex UK

Fund Base Currency

GBP

Share Class Currency

GBP

XD Dates

01-Jan, 01-April, 01-July, 01-Oct

Dividend Pay Dates

28-Feb, 31-May, 31-Aug, 30-Nov

Market Capitalisation	(%)
> €10bn	75.6
€1bn-10bn	20.9
< €1bn	0.0

Charges (%)	Initial	OCF
I Class (GBP)	Nil	1.07


Minimum Investment
I Class (GPB)
£100

ISIN Numbers (GBP)
GB00BYQJX435 (I Acc)
GB00BYQJX104 (I Inc)

Top 10 Holdings	%	Top 10 Countries	%	Top 10 Sectors	%
Novo Nordisk	5.4	France	19.6	Capital Goods	12.7
LVMH	4.3	Germany	15.0	Pharmaceuticals, Biotechnology & Life Sciences	12.2
Sampo	3.6	Netherlands	12.4	Software & Services	9.5
Nordea	3.4	Switzerland	11.0	Consumer Durables & Apparel	8.0
Schneider	3.0	Denmark	8.2	Semiconductors & Semiconductor Equipment	7.5
Wolters Kluwer	2.8	Finland	7.0	Banks	7.1
Capgemini	2.8	United Kingdom	5.2	Commercial & Professional Services	6.2
Nestle	2.7	Sweden	4.4	Diversified Financials	4.3
Roche	2.6	United States	4.1	Technology Hardware & Equipment	4.2
Brenntag	2.5	Italy	3.2	Transportation	4.1
Total Holdings	56	Cash	3.5		

Source: CRUX Asset Management.

Performance: Percentage Growth, since launch (2 November 2015) to 31 August 2022



Source: as at 31 August 2022. © 2022 FE. All Rights Reserved. Total return, Bid-bid in GBP, net income reinvested.

Note: These figures refer to the past and past performance is not a reliable indicator of future results.

TM CRUX European Fund

(Continued)



Disc Yr Perf* (%)	YTD	2021	2020	2019	2018	2017	Since launch
TM CEF I Acc GBP	-17.1%	15.4%	11.4%	19.4%	-14.3%	15.7%	53.6%
IA Europe ex UK	-14.4%	15.8%	10.3%	20.3%	-12.2%	17.3%	61.8%

Disc Yr Perf* (Discrete Year Performance)

Source: as at 31 August 2022. © 2022 FE. All Rights Reserved. Total return, Bid-bid in GBP, net income reinvested. Discrete performance data may change due to final dividend information being received after quarter end.

Note: These figures refer to the past and past performance is not a reliable indicator of future results.

Bright spots during August included Equinor which rallied with rising European gas prices and Sampo which raised guidance and showed why Nordic insurance is an attractive region for disciplined pricing and managing cost inflation. Carlsberg advanced on results showing how price rises offset inflation yet demand remained solid. Outsourcer Majorel reported accelerating growth and is progressing with the Sitel merger. Infineon saw strong growth and margins for microchips due to continued high demand and prices from industry and autos. Deutsche Post released good results and upgraded guidance, with Express DHL seeing resilient volumes as well as passing on inflation to customers. Performance was held back by Schneider on recession concerns even though it raised guidance in July. Novo Nordisk slipped as its new drug Wegovy did not grow quite as fast as hoped in the quarter. In terms of transactions, we disposed of SIG Combibloc after a strong rally, but where two large acquisitions have left it with leverage and inflation will continue to be a challenge. We trimmed Roche and Nestle after holding up well, and topped up recent purchase Merck (which reported good results) and Novo Nordisk after its slight set-back.



James Milne
Fund Manager



Richard Pease
Fund Manager

MSCI
ESG RATINGS



Produced by MSCI ESG Research as of (31 August 2022)

MSCI ESG Research LLC's ("MSCI ESG") Fund Metrics and Ratings (the "information") provide environmental social and governance data with respect to underlying securities within more than 31,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of 1940. MSCI ESG materials have not been submitted to, nor received approval from, the US SEC or any other regulatory body. None of the information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information.

Important Information

Please note the views, opinions and forecasts expressed in this document are based on CRUX's research and analysis at the time of publication. Before entering into an investment agreement in respect of an investment referred to in this document, you should consult your own professional and/or investment adviser. TM CRUX European Fund (the 'Fund') is a sub-fund of TM CRUX OEIC (the 'Company'). The Company is an investment company with variable capital and is a UCITS Scheme. It is incorporated under the Open-Ended Investment Companies Regulations 2001 ('OEIC Regulations') in England and Wales under registry number IC001022. The Company is regulated by the FCA and was authorised on 10 December 2014. The FP CRUX European Fund was renamed the TM CRUX European Fund on 28 September 2019. This information is only directed at persons residing in jurisdictions where the Company and its shares are authorised for distribution or where no such authorisation is required. The KIID and Fund Prospectus and other documentation related to the Scheme, are available from the CRUX website www.cruxam.com. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested. If you invest through a third party provider you are advised to consult them directly as charges, performance and terms and conditions may differ materially to those shown on this document.

Please note: Due to rounding the figures in the holdings breakdown may not add up to 100%. Unless otherwise indicated all figures sourced from Financial Express, Datastream, State Street and CRUX Asset Management Ltd. Third party data is believed to be reliable, but its completeness and accuracy is not guaranteed.

This document has been approved under Section 21 of the Financial Services and Markets Act 2000 by CRUX Asset Management Ltd. This document is issued by CRUX Asset Management Ltd which is registered in England and Wales (Company no. 08697189) and whose registered address is 48 Pall Mall, London, SW1Y 5JG. It is authorised and regulated by the Financial Conduct Authority (FRN 623757)

These figures refer to the past and past performance is not a reliable indicator of future results.

The Authorised Corporate Director is Thesis Unit Trust Management Limited, Exchange Building, St John's Street, Chichester, West Sussex, PO19 1UP. Authorised and regulated by the Financial Conduct Authority.

To obtain monthly commentary from our fund managers please visit: www.cruxam.com/news

